Analyst initiations: SPWR, ESLR and ABT

Filed under: Analyst reports, Abbott Laboratories (ABT), Analyst initiations

MOST NOTEWORTHY:

• Citigroup believes SunPower (NASDAQ: SPWR) is faced with high cell production costs, its silicon cost and installation cost advantages are increasingly commoditized and finds the risk/reward even at current levels. Shares were initiated with a Hold rating and $105 target.
  


• Citigroup believes Evergreen Solar (NASDAQ: ESLR) faces significant financing requirements over the next few years, making it difficult to see a sustained period of EPS growth beyond the $1 range. The firm sees downside to $5/share. Shares were assumed with a Sell rating and $8 target.
  


• UBS started Abbott Lab (NYSE: ABT) with a Buy rating and $61 target. The firm is positive on Humira potential growth and expects Xience to drive vascular operating margins to positive.

• Lazard initiated Cree (NASDAQ: CREE) and Rubicon Tech (NASDAQ: RBCN) with Hold ratings.
  


• BMO Capital started Smith & Nephew (NYSE: SNN) with an Outperform rating and $70 target.

Permalink | Email this | Comments

<map name="google_ad_map_145-1191118"><area href="http://imageads.googleadservices.com/pagead/imgclick/145-1191118?pos=0" shape="rect" coords="1,2,367,28" /><area href="http://services.google.com/feedback/abg" shape="rect" coords="384,10,453,23" /></map>